Sandra and Edward Meyer Cancer Center

You are here


Peter Martin, M.D., Talks Trial of Oral Azacitidine Plus R-CHOP in High Risk DLBCL

Friday, January 5, 2018

Peter Martin, M.D., discusses a trial of the combination of oral azacitidine (CC-486) and R-CHOP in diffuse large B-cell lymphoma (DLBCL). This was a phase I, open-label, multicenter trial of oral azacitidine plus R-CHOP in patients with high-risk, previously untreated DLBCL, grade 3B follicular lymphoma, or transformed lymphoma.